The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results

Area of Science:

• Cardiovascular Research
• Clinical Trials
• Lipid Metabolism

Background:

• Atherosclerosis progression is a major cardiovascular concern.
• Effective lipid-lowering strategies are crucial for managing arterial disease.
• The Cholesterol Lowering Atherosclerosis Study (CLAS) aimed to evaluate a specific therapeutic approach.

Purpose of the Study:

• To test the hypothesis that aggressive lowering of LDL cholesterol and increasing HDL cholesterol can reverse or slow atherosclerosis.
• To determine if combined colestipol and niacin therapy significantly alters coronary, carotid, and femoral artery atherosclerosis.
• To assess the impact on coronary bypass graft lesions.

Main Methods:

• Prospective, placebo-controlled, angiographic trial design.
• Randomization of 188 subjects to diet plus drug (colestipol plus niacin) or diet plus placebo.
• Methodological aspects including population selection, recruitment, experimental design, outcome evaluation, and compliance monitoring were detailed.

Main Results:

• Baseline data showed no significant differences between groups at randomization.
• Subjects were predominantly middle-aged males with elevated cholesterol levels (average 243 mg/dL).
• Average baseline coronary stenosis was equivalent between groups, with 10.6 lesions per subject.

Conclusions:

• The study established a robust methodology for evaluating lipid-lowering therapies on atherosclerosis.
• Baseline characteristics were well-matched, supporting the trial's design integrity.
• The foundation was laid for assessing the efficacy of colestipol plus niacin in the CLAS trial.